XML 73 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended 35 Months Ended
Mar. 31, 2021
Jan. 31, 2021
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Jul. 31, 2017
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jan. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Research and development                   $ 13,558 $ 9,872 $ 9,752  
Noncurrent liabilities       $ 11,970           12,482 11,970    
Amortization expense for intangible assets                   1,900 2,000 3,100  
Other intangibles, net       14,196           14,604 14,196    
Estimated aggregate amortization expense, 2021                   1,500      
Estimated aggregate amortization expense, 2022                   1,500      
Estimated aggregate amortization expense, 2023                   1,400      
Estimated aggregate amortization expense, 2024                   1,300      
Estimated aggregate amortization expense, 2025                   1,200      
Licenses                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Other intangibles, net       2,361           2,790 2,361    
Lynparza | Licenses                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Other intangibles, net                   1,300      
Lenvima | Licenses                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Other intangibles, net                   1,100      
Adempas | Other Intangible Assets, Net                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Intangible assets                   849      
AstraZeneca                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront and milestone payments                 $ 1,600        
Payments to acquire intangible assets       $ 100   $ 400   $ 250 $ 750        
AstraZeneca | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent payments collaborative arrangement                   2,700      
AstraZeneca | Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent payments collaborative arrangement                   1,400      
AstraZeneca | Lynparza | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable future contingent payments collaborative arrangement                   400 1,000    
Liabilities                   400      
Milestone payments made to collaborative partner                   550 200 250  
AstraZeneca | Lynparza | Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments made to collaborative partner                   160 60 140  
Eisai                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront and milestone payments             $ 750            
Payments to acquire intangible assets     $ 200   $ 325                
Research and development                       1,400  
Eisai | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent payments collaborative arrangement                   2,600      
Eisai | Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent payments collaborative arrangement                   125      
Eisai | Lenvima | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable future contingent payments collaborative arrangement                   400 950    
Liabilities                   400      
Milestone payments made to collaborative partner                   500 50    
Eisai | Lenvima | Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments made to collaborative partner                   10   250  
Eisai | Forecast                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Payments to acquire intangible assets $ 125                       $ 650
Bayer AG | Adempas | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable future contingent payments collaborative arrangement                     $ 725    
Milestone payments made to collaborative partner                   $ 375   $ 350  
Subsequent Event | Bayer AG | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable future contingent payments collaborative arrangement   $ 400                      
Liabilities   $ 400                     $ 400